Blog


Eagle Biosciences is excited to highlight the Double-Stranded RNA (dsRNA) ELISA Assay Kit from Krishgen Biosystems! This kit allows sensitive and selective detection of dsRNA molecules (larger than 30-40 bp), independent of their nucleotide composition and sequence. Check out the assay background and highlights below!


Background

Double-stranded (ds) RNA formation is a hallmark of viral infections that is essential for the induction of innate immunity. dsRNA is also involve in gene silencing and produced as a side product during in-vitro transcription-based RNA synthesis. The increasing importance of in vitro-transcribed (IVT) mRNA for synthesizing the encoded therapeutic protein in vivo demands the manufacturing of pure mRNA products. The major contaminant in the IVT mRNA is double-stranded RNA (dsRNA). The nuclei of human cells contain dsRNA that plays a role in natural biological processes however, when dsRNA enters the cells, from the extracellular milieu into their endosome or cytoplasm, it is sensed as a viral invader. All cells are capable of responding to dsRNA through sensors and effectors. Therefore, the elimination of dsRNA from the IVT mRNA is crucial to improve translation of the administered mRNA and to limit induction of cytokines.

This assay works on the sandwich-ELISA principle and uses both J2 (IgG2a) antibody to dsRNA and K2 antibody to dsRNA as capture and detection antibodies. dsRNA-recognition is independent of the sequence and nucleotide composition of the antigen.


dsRNA ELISA Kit Highlights

  • Pre-coated wells
  • Better specificity – using a direct sandwich assay protocol
  • Ready-to-Use – all components included, and prepared

If you have any questions about this kit or any of our other offerings, contact us here.

Dopamine Sensitive ELISA Assay Utilized in Recent Publication

The Eagle Bioscience’s Noradrenaline (Norepinephrine) Sensitive ELISA was utilized in two recent publications! On study explored how norepinephrine transporter defects lead to sympathetic hyperactivity in familial dysautonomia models and the other focused on the effects of a caffeine containing pre-workout supplement on β2-adrenergic and MAPK signaling during resistance exercise. Check out the full text and abstracts below.


Norepinephrine transporter defects lead to sympathetic hyperactivity in Familial Dysautonomia models

Abstract

Familial dysautonomia (FD), a rare neurodevelopmental and neurodegenerative disorder affects the sympathetic and sensory nervous system. Although almost all patients harbor a mutation in ELP1, it remains unresolved exactly how function of sympathetic neurons (symNs) is affected; knowledge critical for understanding debilitating disease hallmarks, including cardiovascular instability or dysautonomic crises, that result from dysregulated sympathetic activity. Here, we employ the human pluripotent stem cell (hPSC) system to understand symN disease mechanisms and test candidate drugs. FD symNs are intrinsically hyperactive in vitro, in cardiomyocyte co-cultures, and in animal models. We report reduced norepinephrine transporter expression, decreased intracellular norepinephrine (NE), decreased NE re-uptake, and excessive extracellular NE in FD symNs. SymN hyperactivity is not a direct ELP1 mutation result, but may connect to NET via RAB proteins. We found that candidate drugs lowered hyperactivity independent of ELP1 modulation. Our findings may have implications for other symN disorders and may allow future drug testing and discovery.

Wu, HF., Yu, W., Saito-Diaz, K. et al. Norepinephrine transporter defects lead to sympathetic hyperactivity in Familial Dysautonomia models. Nat Commun 13, 7032 (2022). https://doi.org/10.1038/s41467-022-34811-7


The effects of a caffeine containing pre-workout supplement on β2-adrenergic and MAPK signaling during resistance exercise

Abstract

Aim: The acute myocellular responses of caffeine supplementation during resistance exercise (RE) have not been investigated. β2-Adrenergic receptors (β2AR) may be a target of the stimulatory effects of caffeine and stimulate bioenergetic pathways including protein kinase A (PKA), and mitogen-activated protein kinases (MAPK).
Purpose: Elucidate the effects of pre-workout supplementation on signaling responses to an acute RE bout.
Methods: In a randomized, counter-balanced, double-blind, placebo-controlled, within-subject crossover study, ten resistance-trained males (mean ± SD; age = 22 ± 2.4 years, height = 175 ± 7 cm, body mass = 84.1 ± 11.8 kg) consumed a caffeine containing multi-ingredient pre-workout supplement (SUPP) or color and flavor matched placebo (PL) 60 min prior to an acute RE bout of barbell back squats. Pre- and post-exercise muscle biopsies were analyzed for the phosphorylation (p-) of β2AR, PKA, and MAPK (ERK, JNK, p38). Epinephrine was determined prior to supplementation (baseline; BL), after supplementation but prior to RE (PRE), and immediately after RE (POST).
Results: Epinephrine increased at PRE in SUPP (mean ± SE: 323 ± 34 vs 457 ± 68 pmol/l; p = 0.028), and was greatest at POST in the SUPP condition compared to PL (5140 ± 852 vs 2862 ± 498 pmol/l; p = 0.006). p-β2AR and p-MAPK increased post-exercise (p < 0.05) with no differences between conditions (p > 0.05). Pearson correlations indicated there was a relationship between epinephrine and p-β2AR in PL (r = − 0.810; p = 0.008), and p-β2AR and ERK in SUPP (r = 0.941; p < 0.001).
Conclusion: Consumption of a caffeine containing pre-workout supplement improves performance, possibly through increases in pre-exercise catecholamines. However, the acute myocellular signaling responses were largely similar post-exercise.

Nicoll, J.X., Fry, A.C. & Mosier, E.M. The effects of a caffeine containing pre-workout supplement on β2-adrenergic and MAPK signaling during resistance exercise. Eur J Appl Physiol 123, 585–599 (2023). https://doi.org/10.1007/s00421-022-05085-0


If you have any questions about our Noradrenaline (Norepinephrine) Sensitive ELISA or our other offerings, please contact us here.

Dopamine Sensitive ELISA Assay Utilized in Recent Publication

The Eagle Bioscience’s High Sensitive CRP ELISA was utilized in a recent publication exploring risk factors for cardiometabolic disease in professional firefighters. Check out the full text and abstract below.


Abstract

Objective: Firefighters are plagued with cardiometabolic disease (CMD). Obesity, poor cardiorespiratory and muscular fitness, and blood lipids (LDL-C, triglycerides, low HDL-C) are risk factors for CMD. However, markers of oxidative stress, inflammation and insulin resistance can provide further insight regarding CMD risk.

Methods: This study investigated the relationships between fitness metrics (cardiorespiratory and muscular fitness, percent body fat, waist circumference), blood lipids, blood pressure, and years of experience as a firefighter to blood markers of insulin resistance: (homeostatic model assessment for insulin resistance, HOMA-IR), oxidative stress: advanced oxidation protein products (AOPP) and inflammation: C-reactive protein (CRP).

Results: Waist circumference and blood concentrations of triglycerides were significantly related to AOPP and HOMA-IR. Cardiorespiratory fitness was inversely related to AOPP, HOMA-IR and CRP.

Conclusion: These findings demonstrate the importance of high cardiorespiratory fitness and low waist circumference to reduce markers of CMD.

McAllister, Matthew J., et al. “Risk Factors for Cardiometabolic Disease in Professional Firefighters.” Journal of Occupational & Environmental Medicine, Publish Ahead of Print, 2022, https://doi.org/10.1097/jom.0000000000002743.


If you have any questions about the High Sensitive CRP ELISA or our other offerings, please contact us here.

Dopamine Sensitive ELISA Assay Utilized in Recent Publication

The Eagle Bioscience’s Ultra-Sensitive Streptavidin Coated Clear 96 Well Microplate was utilized in a recent publication that explored non-viral precision T cell receptor replacement for personalized cell therapy. Check out the full text and abstract below.


Abstract

T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells. Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision genome-editing to simultaneously knockout the two endogenous TCR genes TRAC (which encodes TCRα) and TRBC (which encodes TCRβ). We also inserted into the TRAC locus two chains of a neoantigen-specific TCR (neoTCR) isolated from circulating T cells of patients. The neoTCRs were isolated using a personalized library of soluble predicted neoantigen–HLA capture reagents. Sixteen patients with different refractory solid cancers received up to three distinct neoTCR transgenic cell products. Each product expressed a patient-specific neoTCR and was administered in a cell-dose-escalation, first-in-human phase I clinical trial (NCT03970382). One patient had grade 1 cytokine release syndrome and one patient had grade 3 encephalitis. All participants had the expected side effects from the lymphodepleting chemotherapy. Five patients had stable disease and the other eleven had disease progression as the best response on the therapy. neoTCR transgenic T cells were detected in tumor biopsy samples after infusion at frequencies higher than the native TCRs before infusion. This study demonstrates the feasibility of isolating and cloning multiple TCRs that recognize mutational neoantigens. Moreover, simultaneous knockout of the endogenous TCR and knock-in of neoTCRs using single-step, non-viral precision genome-editing are achieved. The manufacture of neoTCR engineered T cells at clinical grade, the safety of infusing up to three gene-edited neoTCR T cell products and the ability of the transgenic T cells to traffic to the tumors of patients are also demonstrated

Foy, Susan P., et al. “Non-Viral Precision T Cell Receptor Replacement for Personalized Cell Therapy.” Nature, 2022, https://doi.org/10.1038/s41586-022-05531-1.


If you have any questions about the Ultra-Sensitive Streptavidin Coated Clear 96 Well Microplate or our other offerings, please contact us here.

Dopamine Sensitive ELISA Assay Utilized in Recent Publication

The Eagle Bioscience’s Pregnenolone ELISA Assay was utilized in a recent publication that explored the effects of pregnenolone on provoked alcohol cravings, anxiety, HPA axis and autonomic arousal in individuals with alcohol use disorder. Check out the full text and abstract below.


Abstract

Rationale: Chronic alcohol intake down-regulates GABAergic transmission and reduces levels of neuroactive steroids. These changes are associated with greater stress dysregulation and high alcohol craving which in turn increases relapse risk.

Objectives: This study tested whether potentiation of the neurosteroid system with pregnenolone (PREG), a precursor to neuroactive steroids and known to increase GABAergic transmission, will normalize chronic alcohol-related stress adaptations in the hypothalamic–pituitary–adrenal (HPA) axis and autonomic responses and reduce alcohol craving to significantly impact relapse risk.

Methods: Forty-three treatment-seeking individuals with alcohol use disorder (AUD) were randomized to placebo (PBO) or supraphysiologic pregnenolone doses of 300 mg or 500 mg treatment using a parallel-between subject design as part of a larger 8-week pilot clinical trial. In week 2, they participated in a 3-day laboratory experiment where on each day they self-administered the assigned study drug in the laboratory and were then exposed to 5-min personalized guided imagery provocation of stress, alcohol, or neutral/relaxing cues, one condition per day on separate days, in a random, counterbalanced order. Repeated assessments of alcohol craving, anxiety, HPA axis, heart rate (HR), systolic (SBP), and diastolic blood pressure (DBP) and serum pregnenolone levels were made on each day.

Results: Pregnenolone levels were significantly increased in the PREG groups versus PBO. PREG treatment decreased stress- and alcohol cue- induced craving and dose-specifically reduced stress-induced anxiety in the 300 mg/day group. Both PREG doses compared to PBO also normalized CORT/ACTH and increased stress-induced HR, stress- and cue-induced SBP, and in the 300 mg PREG group cue-induced DBP responses relative to neutral condition.

Conclusions: Findings indicate that pregnenolone decreases stress- and alcohol cue-provoked craving and normalizes HPA axis and autonomic arousal in individuals with AUD, thereby supporting the need for further assessment of pregnenolone in the treatment of AUD.

Milivojevic, Verica, et al. “Pregnenolone Effects on Provoked Alcohol Craving, Anxiety, Hpa Axis, and Autonomic Arousal in Individuals with Alcohol Use Disorder.” Psychopharmacology, vol. 240, no. 1, 2022, pp. 101–114., https://doi.org/10.1007/s00213-022-06278-3.


If you have any questions about the Pregnenolone ELISA Assay or our other offerings, please contact us here.

Dopamine Sensitive ELISA Assay Utilized in Recent Publication

The Eagle Bioscience’s Histamine ELISA Assay was highlighted in a recent publication that explored how histamine deficiency deteriorates LPS-induced periodontal diseases in mice. Check out the full text and abstract below.


Abstract

Histamine is a versatile biogenic amine, generated by the unique enzyme histidine decarboxylase (Hdc). Accumulating evidence has proven that histamine plays important roles in numerous biological and pathophysiological processes. However, the role and mechanism of Hdc/Histamine signaling in periodontal diseases remain unclear. In our current study, the concentration of histamine increased in the serum, and Hdc gene expression was upregulated in the gingiva of WT mice with LPS-induced periodontal inflammation. With HdcGFP mice, we identified that Hdc/GFP in the periodontium was expressed in CD11b+ myeloid cells, rather than in tryptase-positive mast cells. Hdc-expressing CD11b+Gr-1+ neutrophils significantly increased in the peripheral blood of HdcGFP mice one day after LPS injection. Lack of histamine in Hdc-/- mice not only promoted the activation and infiltration of more CD11b+ cells into the peripheral blood but also upregulated mRNA expression levels of IL-1β, IL-6, MCP-1and MMP9 in the gingiva compared to WT mice one day after LPS stimulation. 28 days after LPS treatment, we observed that Hdc-/- mice exhibited more alveolar bone loss and more osteoclasts than WT mice, which was slightly ameliorated by the administration of exogenous histamine. In vivo and in vitro mechanistic studies revealed that the mRNA expression levels of proinflammatory cytokines and protein levels of NLRP3, Caspase-1, and cleaved-Caspase-1 were upregulated after blocking histamine receptor 1 and 2, especially histamine receptor 1. Taken together, CD11b+Gr-1+ neutrophils are the predominant Hdc-expressing sites in periodontal inflammation, and deficiency of endogenous histamine in Hdc-/- mice exacerbates the destruction of the periodontium. Disruption of the histamine/H1R/H2R axis aggravates the inflammatory immune response via NLRP3/Casapse-1 pathway.

Song, Fujie., et al. “Histamine Deficiency Deteriorates LPS-Induced Periodontal Diseases in a Murine Model via NLRP3/Caspase-1 Pathway.” International Immunopharmacology, vol. 115, 2023, p. 109630., https://doi.org/10.1016/j.intimp.2022.109630.


If you have any questions about our Histamine ELISA Assay or our other offerings, please contact us here.

The Eagle Bioscience’s 25-OH Vitamin D ELISA Assay Kit has been used in a number of recent publications! These studies range from exploring the effects of vitamin D on cellular responses, molecular immunity, and mycobacterial killing in cattle, to the role of vitamin D, DKK1, hepcidin, and other oxidative stress biomarkers in type 2 diabetes mellitus patients. Check them all out below!


Flores Villalva, Susana. “The Effects of Vitamin D on the Cellular Responses, Molecular Immunity, and Mycobacterial Killing in Cattle.” University College Dublin. School of Agriculture and Food Science, 2022.

Kamel, Amira A., et al. “The Role of Vitamin D, DKK1, Hepcidin and Oxidative Stress Biomarkers in Type 2 Diabetes Mellitus Patients with and without Diabetic Nephropathy.” The Egyptian Journal of Hospital Medicine, vol. 89, no. 2, 2022, pp. 7137–7146.

Blakely, L.P., et al. “Effect of Vitamin D Source and Amount on Vitamin D Status and Response to Endotoxin Challenge.” Journal of Dairy Science, vol. 106, no. 2, 2023, pp. 912–926.

Fernández-Lázaro, Diego, et al. “25-Hydroxyvitamin D Serum Levels Linked to Single Nucleotide Polymorphisms (Snps) (RS2228570, RS2282679, rs10741657) in Skeletal Muscle Aging in Institutionalized Elderly Men Not Supplemented with Vitamin D.” International Journal of Molecular Sciences, vol. 23, no. 19, 2022, p. 11846.

Kumar, Abhai, et al. “Vitamin D and Inflammatory Cytokines Association in Mild Cognitive Impaired Subjects.” Neuroscience Letters, vol. 795, 2023, p. 137044.

Stenhouse, Claire, et al. “Uptake of Phosphate, Calcium, and Vitamin D by the Pregnant Uterus of Sheep in Late Gestation: Regulation by Chorionic Somatomammotropin Hormone.” International Journal of Molecular Sciences, vol. 23, no. 14, 2022, p. 7795.


If you have any questions about our 25-OH Vitamin D ELISA Kit or any of our other offerings, contact us here.

Dopamine Sensitive ELISA Assay Utilized in Recent Publication

The Eagle Bioscience’s P1NP ELISA Assay was utilized in a recent publication that explored how maternal vitamin D levels correlate with fetal weight and bone metabolism during pregnancy. Check out the full text and abstract below.


Abstract

Objectives: Vitamin D plays an essential role in neonatal skeletal development and maternal weight gain during pregnancy. We aim to study the association between vitamin D status, maternal weight, and materno-neonatal bone metabolism parameters.

Methods: From January to June 2017, we conducted this cross-sectional study among 103 pregnant women (21–42 years old) and their singletons. The levels of serum 25-(OH)D, PTH, P1NP, OC, and CTX were measured for mothers and neonates (cord blood). Serum vitamin D and OC were measured using chemiluminescence and two-site immunoradiometric assay, respectively. Meanwhile, P1NP, CTX, and PTH were measured by ELISA.

Results: The average serum vitamin D levels from mothers were 15.1 ng/mL during pregnancy and 16.2 ng/mL in the umbilical cord. At baseline, vitamin D deficient mothers were more likely to have higher PTH (36.4 vs. 18 pg/mL; p=0.029) and lower P1NP levels (90 vs. 92.5 ng/mL; p=0.026). Also, vitamin D deficient status was associated with lower fetal weight (3,293 vs. 3,358 g; p=0.019). Maternal weight was significantly correlated with P1NP (65.86 vs. 109.35; p=0.001) and OC (14.52 vs. 18.24; p=0.038), as well as cord vitamin D level (13.31 vs. 18.46; p=0.039) among normal vs. overweight women. No significant differences were found for the correlation between maternal weight and fetal parameters except for fetal weight which significantly increased with the increase in maternal weight (overweight vs. obese women=3,280 vs. 3,560; p=0.06).

Conclusions: Maternal vitamin D status is associated with maternal and neonatal bone metabolism parameters as well as maternal and neonatal weight.

Luo, Lian-mei, Wu, Nan, Zhang, Jun and Yang, Dong. “Maternal vitamin D levels correlate with fetal weight and bone metabolism during pregnancy: a materno-neonatal analysis of bone metabolism parameters” Journal of Perinatal Medicine, 2022. https://doi.org/10.1515/jpm-2022-0068


If you have any questions about the P1NP ELISA Assay or our other offerings, please contact us here.

The MedFrontier Intact FGF-23 Assay is developed and manufactured by Minaris Medical! This assay kit is a reliable test that provides a simple and quick assay procedure that yields a broad dynamic range.


What is FGF-23?

FGF-23 (Fibroblast Growth Factor 23) is a protein belonging to the fibroblast growth factor family. FGF-23 is involved in the regulation of phosphorus metabolism. FGF-23 has a molecular weight of approximately 32 kDa. FGF-23 is produced in bone cells. In vivo, FGF-23 is secreted into circulation. A full-length active FGF-23 protein may undergo proteolytic cleavage to generate an inactive c-terminal fragment. The MedFrontier Intact FGF-23 Assay measures ONLY the full-length active form (intact form).

Why Measure FGF-23?

Phosphate plays a critical role in the formation and growth of bones in children and maintaining strength in adults. If there is an imbalance of FGF-23 within the bloodstream, it can cause hyper- and hypophosphatemia. These conditions have been linked to Rickets, osteomalacia, and impaired renal function to name a few.


About the MedFrontier Intact FGF-23 Assay Kit

This is a sandwich Chemiluminescence enzyme immunoassay (CLEIA) kit by using two anti-human FGF-23 mouse monoclonal antibodies. When serum is added to a plate well coated with anti-human FGF-23 mouse monoclonal antibodies, FGF-23 is captured by the immobilized antibodies (1st reaction). After the 1st reaction, the plate is washed. Then, ALP-labeled anti-human FGF-23 mouse monoclonal 2nd antibodies against FGF-23 react to FGF-23 antigens captured by the immobilized antibodies (2nd reaction). After the 2nd reaction, the plate is washed and light detection is performed after adding the luminescence reagent. Each active well of the plate is measured using a luminescence microplate reader and relative light units (RLU) are obtained. The concentration of FGF-23 in serum is calculated with a standard curve generated using the FGF-23 Standard 1 to 6.

Check out the product flyer to learn more!


If you have any questions about this kit or any of our other offerings, contact us here.

We are excited to bring you the newest addition to our line of Complement Assays, two new Factor P assays – one quantitative and one functional. Developed and Manufactured by Svar Life Science, these kits are designed to work optimally together. These assays are ideal for assisting in the development of next-generation complement therapies!

In addition to measuring the properdin (Factor P) concentration and determining its functionality, the Factor P assays can be easily adapted for more in-depth studies, granting a closer look at the amplification loop of the complement system.


About Factor P

Factor P (Complement P, Properdin, FP) is a positive regulator and an initiator of the alternative pathway (AP) for complement activation. It binds surface-bound C3 and C5 convertases and stabilizes them to amplify the activation cascade1. Factor P binding increases the half-life of the convertase complex approximately 10-fold2. It is suggested, however debated, that Factor P also can initiate complement activation by binding for example cell surfaces or certain biological substrates, recruiting C3b or C3(H2O) and Factor B and thus initiate the AP pathway1,3. Factor P opposes the negative regulation of Factor H that enhances the dissociation of C3b and Bb and mediates Factor I cleavage of C3b to the inactive iC3b3 (Figure 1).


Figure 1: Factor P as stabilizer and initiator of the alternative complement pathway (left) and the opposing negative regulation by Factor H3 (right).

Factor P is not produced in hepatocytes as most complement proteins, but instead by several cell types including monocytes, macrophages, T-cells and granulocytes. It is likely that transient increased concentration of Factor P enhances the AP upon local stimuli4. For example, neutrophils have Factor P-containing granules that are secreted upon stimulation and can enhance the platelet-granulocyte aggregate formation1. In plasma, Factor P is present in a concentration of approximately 4-25 µg/mL5. Factor P is an elongated 53 kDa glycoprotein that oligomerizes in vivo to dimers, trimers or tetramers (P2, P3 and P4) in a ratio of 26:54:20 (P2:P3:P4) in head to tail structures5,6. Mutations, deficiencies, protein levels as well as protein deposits of Factor P are connected to diseases and disorders summarized by Chen et al 3. Deficiencies generally increase the susceptibility for meningococcal disease and other infectious diseases7. Altered serum levels have been associated with for example C3 glomerulopathy, Lupus Nephritis, sepsis and chronic heart failure and IgA nephropathy8.


References

  1. Blatt, A. Z.; Pathan, S.; Ferreira, V. P. Properdin: A Tightly Regulated Critical Inflammatory Modulator. Immunol Rev 2016, 274 (1), 172–190. https://doi.org/10.1111/imr.12466.
  2. Fearon, D. T.; Austen, K. F. Properdin: Binding to C3b and Stabilization of the C3b-Dependent C3 Convertase. J Exp Med 1975, 142 (4), 856–863.
  3. Chen, J. Y.; Cortes, C.; Ferreira, V. P. Properdin: A Multifaceted Molecule Involved in Inflammation and Diseases. Mol. Immunol. 2018, 102, 58–72. https://doi.org/10.1016/j.molimm.2018.05.018.
  4. Cortes, C.; Ohtola, J. A.; Saggu, G.; Ferreira, V. P. Local Release of Properdin in the Cellular
    Microenvironment: Role in Pattern Recognition and Amplification of the Alternative Pathway of Complement. Front Immunol 2013, 3. https://doi.org/10.3389/fimmu.2012.00412.
  5. Pangburn, M. K. Analysis of the Natural Polymeric Forms of Human Properdin and Their Functions in Complement Activation. The Journal of Immunology 1989, 142 (1), 202–207.
  6. Smith, C. A.; Pangburn, M. K.; Vogel, C. W.; Müller-Eberhard, H. J. Molecular Architecture of Human Properdin, a Positive Regulator of the Alternative Pathway of Complement. J. Biol. Chem. 1984, 259 (7), 4582–4588.
  7. Fijen, C. A. P.; van den Bogaard, R.; Schipper, M. Properdin Defciency: Molecular Basis and Disease Association. Molecular Immunology 1999, 36, 863–867.
  8. Michels, M. A. H. M.; Volokhina, E. B.; van de Kar, N. C. A. J.; van den Heuvel, L. P. W. J. The Role of Properdin in Complement-Mediated Renal Diseases: A New Player in Complement-Inhibiting Therapy? Pediatr Nephrol 2019, 34 (8), 1349–1367. https://doi.org/10.1007/s00467-018-4042-z.

If you have questions about these new items, or any of our other offerings, contact us here.